Home / Deep Research / Granular Cell Tumor

Granular Cell Tumor

1. Disease Information

2026-06-30
Falcon MONDO:0006235 Model: Edison Scientific Literature 16 citations

1. Disease Information

Overview

Granular cell tumor (GCT) is a rare neuroectodermal soft tissue neoplasm derived principally from Schwann cells of the peripheral nervous system (franca2021whole‐exomesequencingreveals pages 1-4, moniruddin2023granularcelltumors pages 1-3). First described in 1926, GCTs were originally termed "granular cell myoblastoma" based on the erroneous belief that they originated from skeletal muscle; they are now recognized as neural in origin based on immunohistochemical and ultrastructural evidence showing S-100 protein positivity and features consistent with Schwann cell differentiation (torrado2023antiangiogenicsinmalignant pages 1-2, moniruddin2023granularcelltumors pages 1-3). GCTs represent approximately 0.5% of all soft tissue sarcomas and are overwhelmingly benign (~98%), with only approximately 2% classified as malignant (torrado2023antiangiogenicsinmalignant pages 1-2, moniruddin2023granularcelltumors pages 1-3).

Key Identifiers

The following table provides a summary of core disease characteristics:

Table (click to expand)
Category Granular Cell Tumor (GCT) summary
Disease name Granular cell tumor (GCT)
MONDO identifiers MONDO:0006235 granular cell tumor; MONDO:0003250 benign granular cell tumor; MONDO:0002291 cutaneous granular cell tumor; MONDO:0003251 esophageal granular cell tumor; MONDO:0003256 neurohypophysis granular cell tumor (OpenTargets Search: granular cell tumor)
Other identifiers ICD-10 and MeSH were not established in the retrieved evidence set; use MONDO above and site-specific coding in implementation workflows when needed (OpenTargets Search: granular cell tumor)
Common synonyms Abrikossoff tumor; granular cell myoblastoma; granular cell schwannoma; granular cell neurofibroma (historical/alternative usage in literature) (torrado2023antiangiogenicsinmalignant pages 1-2, moniruddin2023granularcelltumors pages 1-3)
Evidence source type Primarily aggregated disease-level reviews plus case series/case reports and tumor sequencing studies; not EHR-derived in the retrieved evidence set (franca2021whole‐exomesequencingreveals pages 1-4, torrado2023antiangiogenicsinmalignant pages 1-2, moniruddin2023granularcelltumors pages 4-5)
Cell of origin / current understanding Usually a Schwann-cell-derived neuroectodermal soft tissue neoplasm; neural GCTs are typically S100-positive. Rare non-neural GCTs are described and are often S100-negative/vimentin-positive (franca2021whole‐exomesequencingreveals pages 1-4, moniruddin2023granularcelltumors pages 4-5, moniruddin2023granularcelltumors pages 1-3)
Frequency / epidemiology Ultra-rare tumor; estimated at ~0.5% of all soft tissue sarcomas. Most tumors are benign (~98%); malignant tumors are rare (~2%). Female predominance is consistently reported; peak incidence is usually in the 4th-6th decades, though cases occur across ages (torrado2023antiangiogenicsinmalignant pages 1-2, moniruddin2023granularcelltumors pages 1-3)
Key genetic alterations Recurrent loss-of-function alterations in ATP6AP1, ATP6AP2, and ATP6V0C are a major molecular signature; V-ATPase pathway disruption is reported in up to ~72% of GCTs. Oral GCT sequencing also identified ATP6AP1 frameshift c.746_749del p.P249Hfs*4 and ATP6V1A p.D290N, plus variants in lysosomal/autophagosomal genes (franca2021whole‐exomesequencingreveals pages 1-4, franca2021whole‐exomesequencingreveals pages 4-6, torrado2023antiangiogenicsinmalignant pages 4-6, torrado2023antiangiogenicsinmalignant pages 2-4, franca2021whole‐exomesequencingreveals pages 11-15)
Key immunohistochemistry markers Typical positive markers: S100, SOX10, CD68, inhibin, nestin, calretinin; additional reported positivity includes NSE, CD57, CD63/NKI-C3, vimentin. Myogenic and melanocytic markers are generally negative or only focally positive in rare cases (torrado2023antiangiogenicsinmalignant pages 2-4, palicelli2022s100immunohistochemicalpositivity pages 6-8, torrado2023antiangiogenicsinmalignant pages 1-2)
Histopathology Non-encapsulated/infiltrative nests or sheets of polygonal cells with abundant eosinophilic granular cytoplasm; PAS-positive, diastase-resistant lysosomal granules; Pustulo-ovoid bodies of Milian; overlying pseudoepitheliomatous hyperplasia may occur (moniruddin2023granularcelltumors pages 1-3, torrado2023antiangiogenicsinmalignant pages 2-4, moniruddin2023granularcelltumors pages 3-4)
Classification system Fanburg-Smith criteria: necrosis, mitotic activity >2/10 HPF, spindle cells, nuclear pleomorphism, vesicular nuclei with prominent nucleoli, and high nuclear-to-cytoplasmic ratio. 0 criteria = benign; 1-2 = atypical; ≥3 = malignant. Ki-67 is usually <5% in benign, 5-10% in atypical, and ~10-50% in malignant GCTs (torrado2023antiangiogenicsinmalignant pages 2-4, moniruddin2023granularcelltumors pages 5-6)
Primary anatomical sites Can arise almost anywhere; commonly superficial soft tissues, especially skin/subcutis and head and neck. Frequent sites include tongue/oral cavity, gastrointestinal tract (especially esophagus), thoracic wall, upper extremities, breast, and less often internal organs (franca2021whole‐exomesequencingreveals pages 1-4, torrado2023antiangiogenicsinmalignant pages 1-2, moniruddin2023granularcelltumors pages 4-5, moniruddin2023granularcelltumors pages 1-3)
Clinical presentation Usually a slow-growing, firm, small (often 5 mm-2 cm), painless/asymptomatic nodule or submucosal swelling; lesions are often solitary, but multifocal disease can occur (franca2021whole‐exomesequencingreveals pages 1-4, moniruddin2023granularcelltumors pages 4-5, moniruddin2023granularcelltumors pages 1-3)
Treatment options Standard treatment for localized/resectable disease is complete surgical excision with negative margins. For unresectable/metastatic malignant GCT, evidence is limited; pazopanib is the best-supported systemic option in recent literature. Cytotoxic chemotherapy has generally shown limited activity; isolated reports describe disease control with PI3K inhibitors or pazopanib-based combinations (moniruddin2023granularcelltumors pages 5-6, torrado2023antiangiogenicsinmalignant pages 6-8, torrado2023antiangiogenicsinmalignant pages 1-2, torrado2023antiangiogenicsinmalignant pages 2-4, torrado2023antiangiogenicsinmalignant pages 8-9)
Pazopanib data In the 2023 review of advanced malignant GCT, pazopanib produced disease control in 8/10 reported patients (80%) and objective RECIST response in 4/10 (40%); median time on therapy was ~7 months (torrado2023antiangiogenicsinmalignant pages 6-8, torrado2023antiangiogenicsinmalignant pages 1-2)
Prognosis: benign GCT Generally excellent after complete excision; recurrence reported at ~2-8% with clear margins, increasing to ~20% with positive margins in some series/reviews (moniruddin2023granularcelltumors pages 5-6)
Prognosis: malignant/metastatic GCT Aggressive course. Local recurrence up to ~32%; metastases in about half of malignant cases, often within 2 years; lungs and bone are common metastatic sites. Reported mortality is ~39% within 3 years for malignant GCT, and median overall survival for metastatic disease is ~10 months (torrado2023antiangiogenicsinmalignant pages 2-4, moniruddin2023granularcelltumors pages 5-6)

Table: This table summarizes the core disease characteristics of granular cell tumor, including identifiers, biology, pathology, clinical presentation, treatment, and prognosis. It is useful as a compact reference for disease knowledge base curation.

2. Etiology

Disease Causal Factors

GCTs arise from Schwann cells of peripheral nerves. The molecular hallmark is loss-of-function mutations in vacuolar ATPase (V-ATPase) component genes, particularly ATP6AP1, ATP6AP2, and ATP6V0C, which are found in approximately 72% of neural GCTs (moniruddin2023granularcelltumors pages 4-5, torrado2023antiangiogenicsinmalignant pages 2-4, torrado2023antiangiogenicsinmalignant pages 1-2). These mutations disrupt endosomal pH regulation, leading to impaired lysosomal acidification and the characteristic accumulation of intracytoplasmic lysosomal granules (franca2021whole‐exomesequencingreveals pages 1-4, franca2021whole‐exomesequencingreveals pages 6-8). Ultrastructurally, the granules are considered autophagosomes or autophagolysosomes consistent with myelin accumulation (franca2021whole‐exomesequencingreveals pages 1-4).

A rare non-neural variant of GCT exists that is S-100 negative and vimentin-positive, suggesting a mesenchymal rather than neural origin (moniruddin2023granularcelltumors pages 1-3).

Risk Factors

Gene-Environment Interactions

No significant gene-environment interactions have been established for GCT. The disease appears driven primarily by somatic genetic events in V-ATPase pathway genes.

3. Phenotypes

Clinical Presentation

GCTs typically present as firm, skin-colored to brownish-red nodules that are usually small (5 mm to 2 cm), slow-growing, and often asymptomatic (moniruddin2023granularcelltumors pages 1-3). Lesions are usually solitary, though multifocal presentations can occur. Submucosal lesions, particularly in the tongue and esophagus, may appear yellowish and smooth-surfaced (moniruddin2023granularcelltumors pages 4-5).

Phenotype Characteristics

  • Subcutaneous/dermal nodule (HP:0001072 - Nodular skin lesion): Most common presentation; firm, painless, small; mild functional impact unless in sensitive locations.
  • Oral/tongue mass (HP:0010280 - Stomatitis or oral lesion): May cause discomfort during eating or speaking in larger lesions; the tongue is the single most common intra-oral site.
  • Dysphagia (HP:0002015): When GCT involves the esophagus; can significantly impact quality of life.
  • Airway obstruction (HP:0002781 - Upper airway obstruction): When GCT involves the larynx; potentially life-threatening in pediatric cases.
  • Pseudoepitheliomatous hyperplasia of overlying epithelium (HP:0000966): A histologic feature that can mimic squamous cell carcinoma clinically and histologically.

Features of Malignancy

Features suggesting malignancy include tumor size >3 cm, local tissue destruction, infiltrative edges, frequent mitoses, and large vesicular nuclei (moniruddin2023granularcelltumors pages 4-5).

4. Genetic/Molecular Information

Causal Genes

The primary molecular signature of GCT involves recurrent inactivating somatic mutations in V-ATPase component genes:

Additional Genetic Alterations

In malignant GCTs specifically, alterations in TP53 and PIK3CA have been reported, distinguishing them from benign tumors (torrado2023antiangiogenicsinmalignant pages 4-6). Additional mutations have been identified in TGFβ pathway genes (TGFBR1, TGFBR2, LTBP2) and MAPK pathway genes (MAP3K15) (torrado2023antiangiogenicsinmalignant pages 4-6). Whole-exome sequencing of oral GCTs has also revealed variants in genes involved in lysosomal biology, including ABCA8, ABCC6, AGAP3, ATG9A, CTSB, DNAJC13, GALC, NPC1, SLC15A3, SLC31A2, and TMEM104 (franca2021whole‐exomesequencingreveals pages 1-4, franca2021whole‐exomesequencingreveals pages 8-11).

The following table details the molecular pathways implicated in GCT pathogenesis:

Table (click to expand)
Pathway/Gene Type of Alteration Functional Consequence Frequency in GCTs Therapeutic Relevance
ATP6AP1 Recurrent somatic loss-of-function; frameshift variants reported Impairs V-ATPase accessory function, disrupts endosomal/lysosomal acidification, promotes lysosomal/autophagosomal granule accumulation characteristic of GCT Part of the recurrent V-ATPase gene set present in ~72% of GCTs; individual-gene frequency varies (torrado2023antiangiogenicsinmalignant pages 1-2, torrado2023antiangiogenicsinmalignant pages 2-4, franca2021whole‐exomesequencingreveals pages 4-6) Core diagnostic molecular feature; mechanistic rationale for targeting downstream RTK signaling, especially pazopanib-sensitive kinase networks (torrado2023antiangiogenicsinmalignant pages 1-2)
ATP6AP2 Recurrent somatic loss-of-function V-ATPase dysfunction with abnormal vesicle acidification; enhances oncogenic signaling downstream of lysosomal stress Part of the recurrent V-ATPase gene set present in ~72% of GCTs (moniruddin2023granularcelltumors pages 4-5, torrado2023antiangiogenicsinmalignant pages 2-4, torrado2023antiangiogenicsinmalignant pages 1-2) Supports targeted therapy rationale via downstream PDGFR-β/SFK/STAT5 activation; also useful diagnostically (torrado2023antiangiogenicsinmalignant pages 1-2, torrado2023antiangiogenicsinmalignant pages 6-8)
ATP6V0C Recurrent inactivating/loss-of-function mutation Disrupts V-ATPase proton pump function and lysosomal homeostasis Included among recurrent V-ATPase alterations in up to ~72% of GCTs (torrado2023antiangiogenicsinmalignant pages 2-4, torrado2023antiangiogenicsinmalignant pages 4-6, franca2021whole‐exomesequencingreveals pages 4-6) Supports pathway-based targeting of consequences of V-ATPase dysfunction rather than direct current gene-specific therapy (torrado2023antiangiogenicsinmalignant pages 4-6, franca2021whole‐exomesequencingreveals pages 6-8)
PDGFR-β Increased phosphorylation/activation downstream of V-ATPase loss Promotes oncogenic signaling, proliferation, and survival in Schwann-lineage tumor cells Activation described as a downstream event in V-ATPase-mutant GCTs; prevalence not independently quantified (torrado2023antiangiogenicsinmalignant pages 4-6, torrado2023antiangiogenicsinmalignant pages 2-4, torrado2023antiangiogenicsinmalignant pages 1-2) Major proposed kinase target; likely contributor to pazopanib activity in advanced/malignant GCT (torrado2023antiangiogenicsinmalignant pages 1-2, torrado2023antiangiogenicsinmalignant pages 8-9)
SFK / Src family kinases Increased phosphorylation/activation Enhances pro-oncogenic signaling downstream of ATP6AP1/2 loss Activation described in V-ATPase-altered GCTs; exact frequency not separately reported (torrado2023antiangiogenicsinmalignant pages 4-6, torrado2023antiangiogenicsinmalignant pages 8-9, torrado2023antiangiogenicsinmalignant pages 1-2) Provides rationale for kinase-directed therapy; dasatinib has been tried clinically but reported ineffective in isolated cases (torrado2023antiangiogenicsinmalignant pages 6-8, torrado2023antiangiogenicsinmalignant pages 4-6)
STAT5a/b Increased signaling/phosphorylation Supports proliferation and survival signaling downstream of lysosomal/V-ATPase dysfunction Activation reported mechanistically; exact frequency not separately reported (torrado2023antiangiogenicsinmalignant pages 4-6, torrado2023antiangiogenicsinmalignant pages 8-9, torrado2023antiangiogenicsinmalignant pages 2-4) Potential downstream vulnerability, though no established STAT5-targeted regimen exists for GCT (torrado2023antiangiogenicsinmalignant pages 4-6, torrado2023antiangiogenicsinmalignant pages 1-2)
PI3K/AKT/mTOR pathway Pathway activation, especially in malignant GCT Promotes cell survival, proliferation, motility, and aggressive behavior Implicated particularly in malignant GCT; population frequency not established (torrado2023antiangiogenicsinmalignant pages 4-6) Clinical relevance supported by a reported PI3K inhibitor achieving ~9 months disease control in one advanced case (torrado2023antiangiogenicsinmalignant pages 6-8, torrado2023antiangiogenicsinmalignant pages 8-9)
TP53 Alterations in malignant GCT Associated with malignant progression and biologic aggressiveness Reported in malignant GCTs; uncommon in benign conventional GCT; exact frequency not established (torrado2023antiangiogenicsinmalignant pages 4-6) May help distinguish malignant biology; no GCT-specific targeted therapy established (torrado2023antiangiogenicsinmalignant pages 4-6)
PIK3CA Alterations in malignant GCT Activates PI3K signaling and may contribute to progression/aggressiveness Reported in malignant GCTs; exact frequency not established (torrado2023antiangiogenicsinmalignant pages 4-6) Supports consideration of PI3K-pathway inhibition in selected advanced cases (torrado2023antiangiogenicsinmalignant pages 6-8, torrado2023antiangiogenicsinmalignant pages 8-9, torrado2023antiangiogenicsinmalignant pages 4-6)
TGFβ pathway (TGFBR1/TGFBR2) Mutations/alterations Suggests additional pathway dysregulation contributing to tumorigenesis Reported as additional alterations; frequency not established (torrado2023antiangiogenicsinmalignant pages 4-6) Currently mainly biologic/interpretive relevance; no standard targeted use in GCT (torrado2023antiangiogenicsinmalignant pages 4-6)
MAPK pathway (including MAP3K15) Mutations/alterations May contribute to tumorigenesis and overlap with syndromic RAS-MAPK biology Reported as additional alterations; frequency not established (torrado2023antiangiogenicsinmalignant pages 4-6, torrado2023antiangiogenicsinmalignant pages 8-9) Supports exploration of MAPK-directed combinations; MEK-inhibitor combinations with pazopanib have been discussed experimentally in sarcoma contexts (torrado2023antiangiogenicsinmalignant pages 13-14, torrado2023antiangiogenicsinmalignant pages 8-9)

Table: This table summarizes the main genetic alterations and signaling pathways implicated in granular cell tumor pathogenesis, with their functional effects and therapeutic implications. It is useful for linking recurrent V-ATPase defects to downstream targetable signaling in malignant or advanced disease.

Somatic vs. Germline Origin

The V-ATPase mutations in GCTs are somatic in origin. However, germline mutations in RAS-MAPK pathway genes (as seen in Noonan syndrome, LEOPARD syndrome, and neurofibromatosis) create a predisposition to GCT development (torrado2023antiangiogenicsinmalignant pages 1-2, torrado2023antiangiogenicsinmalignant pages 8-9).

5. Environmental Information

No specific environmental factors, toxins, lifestyle factors, or infectious agents have been identified as contributing to GCT development. The disease appears driven primarily by somatic genetic alterations.

6. Mechanism / Pathophysiology

Molecular Pathways

The central pathogenic mechanism of GCT involves V-ATPase dysfunction caused by loss-of-function mutations in ATP6AP1/AP2/ATP6V0C genes (torrado2023antiangiogenicsinmalignant pages 2-4, torrado2023antiangiogenicsinmalignant pages 1-2, franca2021whole‐exomesequencingreveals pages 6-8). V-ATPases are multisubunit enzymes responsible for acidifying intracellular compartments and transporting protons across the plasma membrane (franca2021whole‐exomesequencingreveals pages 6-8). When these proton pumps are impaired in Schwann cells, a cascade of pathological events occurs:

  1. Lysosomal dysfunction: Decreased lysosomal acidification leads to impaired degradation of intracellular substrates, resulting in the characteristic accumulation of autophagosomes/autophagolysosomes containing myelin material — the granules that define GCTs (franca2021whole‐exomesequencingreveals pages 1-4, franca2021whole‐exomesequencingreveals pages 6-8, franca2021whole‐exomesequencingreveals pages 8-11).

  2. Downstream oncogenic signaling: V-ATPase dysfunction leads to increased phosphorylation and activation of PDGFR-β, Src family kinases (SFKs), and STAT5a/b, promoting oncogenic signaling, cell proliferation, and survival (torrado2023antiangiogenicsinmalignant pages 4-6, torrado2023antiangiogenicsinmalignant pages 8-9, torrado2023antiangiogenicsinmalignant pages 2-4, torrado2023antiangiogenicsinmalignant pages 1-2).

  3. Transcription factor activation: Lysosomal inhibition activates transcription factors MITF, TFE3, and TFEB (torrado2023antiangiogenicsinmalignant pages 4-6).

  4. S100 protein-mediated proliferation: S100 protein released from damaged Schwann cells activates migration and cell proliferation, reinforcing tumor growth (torrado2023antiangiogenicsinmalignant pages 2-4).

  5. PI3K/AKT/mTOR pathway: Activated by upstream receptor tyrosine kinases (EGFR, HER2, RET, MET, VEGFR), this pathway promotes cell survival, proliferation, and motility, particularly in malignant GCTs (torrado2023antiangiogenicsinmalignant pages 4-6).

Suggested GO Terms

Cell Types Involved

  • CL:0002573 (Schwann cell) — primary cell of origin
  • CL:0000540 (neuron) — associated tissue context

7. Anatomical Structures Affected

Organ Level

GCTs can develop at virtually any anatomical site. The most common locations include (franca2021whole‐exomesequencingreveals pages 1-4, torrado2023antiangiogenicsinmalignant pages 1-2, moniruddin2023granularcelltumors pages 4-5, moniruddin2023granularcelltumors pages 1-3):

  • Skin and subcutaneous tissue (30-40% of cases): Especially the upper body, head and neck (UBERON:0002097 — skin of body)
  • Oral cavity/tongue (most common single intra-oral site): UBERON:0001723 — tongue
  • Gastrointestinal tract (especially esophagus): UBERON:0001043 — esophagus
  • Breast: UBERON:0000310 — breast
  • Respiratory tract (larynx, bronchi): UBERON:0001737 — larynx
  • Sellar/pituitary region (neurohypophysis): UBERON:0002198 — neurohypophysis
  • Other sites: thoracic wall, upper extremities, biliary tract, vulva, orbit, perianal region

Tissue and Cell Level

  • Affected tissue: Peripheral nerve sheath tissue, soft tissue (UBERON:0003714 — neural tissue)
  • Primary cell population: Schwann cells (CL:0002573)
  • Subcellular compartments: Lysosomes (GO:0005764), autophagosomes (GO:0005776), endosomes

8. Temporal Development

Onset

Progression

9. Inheritance and Population

Epidemiology

Genetic Aspects

GCTs are typically sporadic with somatic mutations. However, syndromic associations exist with LEOPARD syndrome, neurofibromatosis, Noonan syndrome, and Watson syndrome, all involving germline RAS-MAPK pathway mutations (torrado2023antiangiogenicsinmalignant pages 1-2, torrado2023antiangiogenicsinmalignant pages 8-9). Multifocal GCTs have been reported and may suggest an underlying genetic predisposition.

10. Diagnostics

Histopathology

The gold standard for diagnosis is histopathological examination of biopsy or excision specimens. Key features include (moniruddin2023granularcelltumors pages 1-3, torrado2023antiangiogenicsinmalignant pages 2-4, moniruddin2023granularcelltumors pages 3-4):

  • Non-encapsulated, infiltrative nests or sheets of large polygonal/polyhedral cells
  • Abundant eosinophilic, finely or coarsely granular cytoplasm (PAS-positive, diastase-resistant)
  • Small, uniform, centrally or eccentrically placed nuclei
  • Pustulo-ovoid bodies of Milian — large eosinophilic granules with clear halos, pathognomonic
  • Overlying pseudoepitheliomatous hyperplasia (can mimic squamous cell carcinoma)
  • Rare mitotic figures in benign tumors

Immunohistochemistry Panel

Neural GCTs are characteristically positive for (torrado2023antiangiogenicsinmalignant pages 2-4, palicelli2022s100immunohistochemicalpositivity pages 6-8, torrado2023antiangiogenicsinmalignant pages 1-2):

  • S-100 protein (consistently positive — most important marker)
  • SOX10 (positive)
  • CD68 (positive)
  • Inhibin-alpha (positive)
  • Nestin (positive)
  • Calretinin (positive)
  • NSE (neuron-specific enolase) and CD57 (positive)
  • CD63/NKI-C3 (positive)
  • TFE3 (positive)
  • Vimentin (positive)
  • Myogenic markers (desmin, SMA): typically negative
  • Melanocytic markers (Melan-A, HMB-45): negative or only rarely focal

Non-neural GCTs are S-100 negative but vimentin-positive (moniruddin2023granularcelltumors pages 1-3).

Fanburg-Smith Classification (Malignancy Grading)

The Fanburg-Smith system evaluates six histologic criteria (torrado2023antiangiogenicsinmalignant pages 2-4, moniruddin2023granularcelltumors pages 5-6): 1. Necrosis 2. Increased mitotic count (>2 per 10 HPF) 3. Spindled tumor cells 4. Nuclear pleomorphism 5. Vesicular nuclei with prominent nucleoli 6. High nuclear-to-cytoplasmic ratio

  • 0 criteria: Benign
  • 1-2 criteria: Atypical
  • ≥3 criteria: Malignant

Ki-67 Proliferation Index

Molecular Diagnostics

Sequencing for ATP6AP1 and ATP6AP2 mutations can be used diagnostically, particularly to distinguish atypical GCT from melanoma in challenging cases. These mutations are considered pathognomonic for GCT (torrado2023antiangiogenicsinmalignant pages 1-2).

Imaging

GCTs typically appear as well-defined submucosal or subcutaneous masses on ultrasound, CT, and MRI. Endoscopic ultrasound is particularly useful for esophageal GCTs.

Differential Diagnosis

11. Outcome / Prognosis

Benign GCT

Malignant GCT

12. Treatment

Surgical Treatment (MAXO:0000004 — surgical procedure)

Complete surgical excision with wide negative margins is the standard of care for all resectable GCTs and is curative for the vast majority of benign tumors (moniruddin2023granularcelltumors pages 5-6, torrado2023antiangiogenicsinmalignant pages 2-4). Margin status is critical: positive margins are associated with significantly higher recurrence rates (moniruddin2023granularcelltumors pages 5-6).

Systemic Therapy for Advanced/Metastatic GCT

Pazopanib (MAXO:0000058 — pharmacotherapy)

Pazopanib, a multi-tyrosine kinase inhibitor targeting VEGFR, PDGFR, and c-KIT, is the best-supported systemic therapy for advanced malignant GCT. In a 2023 systematic review of 10 case reports (torrado2023antiangiogenicsinmalignant pages 6-8, torrado2023antiangiogenicsinmalignant pages 1-2): - Disease control rate: 80% (8/10 patients) - Objective RECIST response rate: 40% (4/10 patients) - Median time on therapy: 7 months - This response rate (40%) substantially exceeds the approximately 6% overall response rate seen with pazopanib in other soft tissue sarcoma subtypes (torrado2023antiangiogenicsinmalignant pages 8-9)

The rationale for pazopanib activity in GCT is linked to the enhanced PDGFR-β phosphorylation resulting from ATP6AP1/AP2 loss-of-function mutations (torrado2023antiangiogenicsinmalignant pages 8-9, torrado2023antiangiogenicsinmalignant pages 1-2).

Chemotherapy

GCTs are generally chemo-resistant. Limited reports describe responses to (moniruddin2023granularcelltumors pages 5-6, torrado2023antiangiogenicsinmalignant pages 8-9): - Gemcitabine plus paclitaxel - Carboplatin plus etoposide However, five previously treated patients who received standard cytotoxic chemotherapy (carboplatin/paclitaxel with cetuximab, gemcitabine/docetaxel, doxorubicin/ifosfamide) showed no objective responses (torrado2023antiangiogenicsinmalignant pages 6-8).

Other Targeted Therapies

Investigational Combination Strategies

Potential combination strategies under discussion include (torrado2023antiangiogenicsinmalignant pages 13-14, torrado2023antiangiogenicsinmalignant pages 8-9): - Pazopanib plus trametinib (MEK inhibitor) - Pazopanib plus abexinostat (HDAC inhibitor) - Immunotherapy combinations (nivolumab with sunitinib; axitinib with pembrolizumab)

Treatment Strategy

No standardized treatment guidelines exist for metastatic GCT due to its ultra-rare nature. Current evidence supports pazopanib as the preferred systemic option for advanced disease (torrado2023antiangiogenicsinmalignant pages 1-2, torrado2023antiangiogenicsinmalignant pages 2-4). Clinical trial participation is encouraged for patients with unresectable or metastatic disease.

13. Prevention

No specific primary or secondary prevention strategies exist for GCT. There are no established screening programs, given the sporadic nature and rarity of the disease. For patients with syndromic associations (Noonan syndrome, neurofibromatosis), general cancer surveillance protocols should be followed. Genetic counseling may be relevant for patients with multifocal GCTs to evaluate for underlying syndromic predisposition (torrado2023antiangiogenicsinmalignant pages 1-2).

14. Other Species / Natural Disease

Veterinary Relevance

GCTs have been reported in domestic animals, notably testicular granular cell tumors in domestic rabbits (Oryctolagus cuniculus). GCTs are uncommon in veterinary pathology and have not been extensively characterized at the molecular level in animals. Comparative pathology studies on peripheral nerve sheath tumors in domestic animals describe Schwann cell-derived lesions in dogs and cats, though GCT-specific data in these species is very limited (OpenTargets Search: granular cell tumor).

15. Model Organisms

No established in vivo animal models (knockout, knock-in, or transgenic) have been developed specifically for GCT. The molecular study of GCTs relies almost exclusively on human clinical specimens, including formalin-fixed paraffin-embedded tissue subjected to whole-exome sequencing and immunohistochemistry (franca2021whole‐exomesequencingreveals pages 1-4, franca2021whole‐exomesequencingreveals pages 4-6). The identification of ATP6AP1/AP2 as driver genes could theoretically enable future model development through conditional knockout approaches in Schwann cell lineage, but such models have not yet been reported in the literature.

Summary

Granular cell tumor is an ultra-rare neuroectodermal neoplasm of Schwann cell origin characterized by a pathognomonic molecular signature of loss-of-function mutations in V-ATPase component genes (ATP6AP1, ATP6AP2, ATP6V0C), present in approximately 72% of cases (moniruddin2023granularcelltumors pages 4-5, torrado2023antiangiogenicsinmalignant pages 1-2). These mutations cause impaired lysosomal acidification and downstream activation of PDGFR-β, SFK, and STAT5 signaling pathways (torrado2023antiangiogenicsinmalignant pages 4-6, torrado2023antiangiogenicsinmalignant pages 2-4). The vast majority of GCTs are benign and curable by surgical excision, while the rare malignant variant carries a poor prognosis with median overall survival of approximately 10 months in the metastatic setting (torrado2023antiangiogenicsinmalignant pages 2-4). Pazopanib represents the most promising systemic therapy for advanced disease, with an 80% disease control rate and 40% objective response rate in reported cases (torrado2023antiangiogenicsinmalignant pages 6-8, torrado2023antiangiogenicsinmalignant pages 1-2). Future research should focus on developing formal clinical trials for pazopanib in GCT, exploring PI3K/mTOR-directed therapy, and creating preclinical models to further elucidate the biology of this rare tumor.

References

  1. (franca2021whole‐exomesequencingreveals pages 1-4): Josiane Alves França, Tenzin Gayden, Eric Bareke, Jean Nunes Santos, Sílvia Ferreira de Sousa, Luciana Bastos‐Rodrigues, Jacek Majewski, Nada Jabado, Ricardo Santiago Gomez, and Carolina Cavalieri Gomes. Whole‐exome sequencing reveals novel vacuolar atpase genes’ variants and variants in genes involved in lysosomal biology and autophagosomal formation in oral granular cell tumors. Dec 2021. URL: https://doi.org/10.1111/jop.13148, doi:10.1111/jop.13148. This article has 13 citations and is from a domain leading peer-reviewed journal.

  2. (moniruddin2023granularcelltumors pages 1-3): ABM Moniruddin, Halima Khatun Doly, Shakila Jannat, Tanvirul Hasan, and MA Rouf. Granular cell tumors. KYAMC Journal, 14:96-101, Oct 2023. URL: https://doi.org/10.3329/kyamcj.v14i02.68561, doi:10.3329/kyamcj.v14i02.68561. This article has 0 citations.

  3. (torrado2023antiangiogenicsinmalignant pages 1-2): Carlos Torrado, Melisa Camaño, Nadia Hindi, Justo Ortega, Alberto R. Sevillano, Gema Civantos, David S. Moura, Alessandra Dimino, and Javier Martín-Broto. Antiangiogenics in malignant granular cell tumors: review of the literature. Cancers, 15:5187, Oct 2023. URL: https://doi.org/10.3390/cancers15215187, doi:10.3390/cancers15215187. This article has 4 citations.

  4. (OpenTargets Search: granular cell tumor): Open Targets Query (granular cell tumor, 0 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

  5. (moniruddin2023granularcelltumors pages 4-5): ABM Moniruddin, Halima Khatun Doly, Shakila Jannat, Tanvirul Hasan, and MA Rouf. Granular cell tumors. KYAMC Journal, 14:96-101, Oct 2023. URL: https://doi.org/10.3329/kyamcj.v14i02.68561, doi:10.3329/kyamcj.v14i02.68561. This article has 0 citations.

  6. (franca2021whole‐exomesequencingreveals pages 4-6): Josiane Alves França, Tenzin Gayden, Eric Bareke, Jean Nunes Santos, Sílvia Ferreira de Sousa, Luciana Bastos‐Rodrigues, Jacek Majewski, Nada Jabado, Ricardo Santiago Gomez, and Carolina Cavalieri Gomes. Whole‐exome sequencing reveals novel vacuolar atpase genes’ variants and variants in genes involved in lysosomal biology and autophagosomal formation in oral granular cell tumors. Dec 2021. URL: https://doi.org/10.1111/jop.13148, doi:10.1111/jop.13148. This article has 13 citations and is from a domain leading peer-reviewed journal.

  7. (torrado2023antiangiogenicsinmalignant pages 4-6): Carlos Torrado, Melisa Camaño, Nadia Hindi, Justo Ortega, Alberto R. Sevillano, Gema Civantos, David S. Moura, Alessandra Dimino, and Javier Martín-Broto. Antiangiogenics in malignant granular cell tumors: review of the literature. Cancers, 15:5187, Oct 2023. URL: https://doi.org/10.3390/cancers15215187, doi:10.3390/cancers15215187. This article has 4 citations.

  8. (torrado2023antiangiogenicsinmalignant pages 2-4): Carlos Torrado, Melisa Camaño, Nadia Hindi, Justo Ortega, Alberto R. Sevillano, Gema Civantos, David S. Moura, Alessandra Dimino, and Javier Martín-Broto. Antiangiogenics in malignant granular cell tumors: review of the literature. Cancers, 15:5187, Oct 2023. URL: https://doi.org/10.3390/cancers15215187, doi:10.3390/cancers15215187. This article has 4 citations.

  9. (franca2021whole‐exomesequencingreveals pages 11-15): Josiane Alves França, Tenzin Gayden, Eric Bareke, Jean Nunes Santos, Sílvia Ferreira de Sousa, Luciana Bastos‐Rodrigues, Jacek Majewski, Nada Jabado, Ricardo Santiago Gomez, and Carolina Cavalieri Gomes. Whole‐exome sequencing reveals novel vacuolar atpase genes’ variants and variants in genes involved in lysosomal biology and autophagosomal formation in oral granular cell tumors. Dec 2021. URL: https://doi.org/10.1111/jop.13148, doi:10.1111/jop.13148. This article has 13 citations and is from a domain leading peer-reviewed journal.

  10. (palicelli2022s100immunohistochemicalpositivity pages 6-8): Andrea Palicelli, Antonio Ramponi, Guido Valente, Renzo Boldorini, Annalisa Balbo Mussetto, and Magda Zanelli. S-100 immunohistochemical positivity in rhabdomyoma: an underestimated potential diagnostic pitfall in routine practice. Diagnostics, 12:892, Apr 2022. URL: https://doi.org/10.3390/diagnostics12040892, doi:10.3390/diagnostics12040892. This article has 6 citations.

  11. (moniruddin2023granularcelltumors pages 3-4): ABM Moniruddin, Halima Khatun Doly, Shakila Jannat, Tanvirul Hasan, and MA Rouf. Granular cell tumors. KYAMC Journal, 14:96-101, Oct 2023. URL: https://doi.org/10.3329/kyamcj.v14i02.68561, doi:10.3329/kyamcj.v14i02.68561. This article has 0 citations.

  12. (moniruddin2023granularcelltumors pages 5-6): ABM Moniruddin, Halima Khatun Doly, Shakila Jannat, Tanvirul Hasan, and MA Rouf. Granular cell tumors. KYAMC Journal, 14:96-101, Oct 2023. URL: https://doi.org/10.3329/kyamcj.v14i02.68561, doi:10.3329/kyamcj.v14i02.68561. This article has 0 citations.

  13. (torrado2023antiangiogenicsinmalignant pages 6-8): Carlos Torrado, Melisa Camaño, Nadia Hindi, Justo Ortega, Alberto R. Sevillano, Gema Civantos, David S. Moura, Alessandra Dimino, and Javier Martín-Broto. Antiangiogenics in malignant granular cell tumors: review of the literature. Cancers, 15:5187, Oct 2023. URL: https://doi.org/10.3390/cancers15215187, doi:10.3390/cancers15215187. This article has 4 citations.

  14. (torrado2023antiangiogenicsinmalignant pages 8-9): Carlos Torrado, Melisa Camaño, Nadia Hindi, Justo Ortega, Alberto R. Sevillano, Gema Civantos, David S. Moura, Alessandra Dimino, and Javier Martín-Broto. Antiangiogenics in malignant granular cell tumors: review of the literature. Cancers, 15:5187, Oct 2023. URL: https://doi.org/10.3390/cancers15215187, doi:10.3390/cancers15215187. This article has 4 citations.

  15. (franca2021whole‐exomesequencingreveals pages 6-8): Josiane Alves França, Tenzin Gayden, Eric Bareke, Jean Nunes Santos, Sílvia Ferreira de Sousa, Luciana Bastos‐Rodrigues, Jacek Majewski, Nada Jabado, Ricardo Santiago Gomez, and Carolina Cavalieri Gomes. Whole‐exome sequencing reveals novel vacuolar atpase genes’ variants and variants in genes involved in lysosomal biology and autophagosomal formation in oral granular cell tumors. Dec 2021. URL: https://doi.org/10.1111/jop.13148, doi:10.1111/jop.13148. This article has 13 citations and is from a domain leading peer-reviewed journal.

  16. (franca2021whole‐exomesequencingreveals pages 8-11): Josiane Alves França, Tenzin Gayden, Eric Bareke, Jean Nunes Santos, Sílvia Ferreira de Sousa, Luciana Bastos‐Rodrigues, Jacek Majewski, Nada Jabado, Ricardo Santiago Gomez, and Carolina Cavalieri Gomes. Whole‐exome sequencing reveals novel vacuolar atpase genes’ variants and variants in genes involved in lysosomal biology and autophagosomal formation in oral granular cell tumors. Dec 2021. URL: https://doi.org/10.1111/jop.13148, doi:10.1111/jop.13148. This article has 13 citations and is from a domain leading peer-reviewed journal.

  17. (torrado2023antiangiogenicsinmalignant pages 13-14): Carlos Torrado, Melisa Camaño, Nadia Hindi, Justo Ortega, Alberto R. Sevillano, Gema Civantos, David S. Moura, Alessandra Dimino, and Javier Martín-Broto. Antiangiogenics in malignant granular cell tumors: review of the literature. Cancers, 15:5187, Oct 2023. URL: https://doi.org/10.3390/cancers15215187, doi:10.3390/cancers15215187. This article has 4 citations.

  18. (cheung2020congenitalgranularcell pages 1-3): Justin M. Cheung and Juan Putra. Congenital granular cell epulis: classic presentation and its differential diagnosis. Head and Neck Pathology, 14:208-211, Mar 2020. URL: https://doi.org/10.1007/s12105-019-01025-1, doi:10.1007/s12105-019-01025-1. This article has 52 citations and is from a peer-reviewed journal.

Artifacts